Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 130 biologics in R&D and 50 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular and Metabolic diseases

Phase 1

Phase 1

  • MEDI5884 cardiovascular

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes
  • MEDI6012 cardiovascular

Phase 3

Phase 3

LCM Projects

LCM Projects

Oncology

Phase 1

Phase 1

  • Imfinzi + AZD1775 solid tumours
  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + MEDI0562 solid tumours
  • Imfinzi + MEDI9197 solid tumours
  • Imfinzi + MEDI9447 solid tumours
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi or Imfinzi + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + Vidaza myelodysplastic syndrome
  • Lynparza + AZD1775 solid tumours
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • Imfinzi solid tumours
  • Imfinzi + AZD5069 pancreatic ductal adenocarcinoma
  • Imfinzi + AZD5069 Imfinzi + AZD9150 head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + tremelimumab hepatocellular carcinoma (liver cancer)
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + AZD6738 gastric cancer
  • Lynparza + Imfinzi MEDIOLA solid tumors
  • Lynparza + cediranib CONCERTO recurrent platinum resistant ovarian cancer
  • MEDI-573 metastatic breast cancer

Phase 3

Phase 3

  • Imfinzi PACIFIC stage III NSCLC
  • Imfinzi + tremelimumab ARCTIC 3rd-line non-small cell lung cancer
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + chemotherapy POSEIDON 1st-line non-small cell lung cancer
  • moxetumomab pasudotox PLAIT hairy cell leukaemia

LCM Projects

LCM Projects

  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer

Respiratory

Phase 1

Phase 1

  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

Other

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI4893 prevention of nosocomial Staphylococcus aureus pneumonia
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

Terminations

  • MEDI8111 trauma/bleeding


AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.